Chemoinformaics analysis of 3,4,5,7-tetrahydroxyflavan-3-ol
| Molecular Weight | 290.271 | nRot | 1 |
| Heavy Atom Molecular Weight | 276.159 | nRig | 17 |
| Exact Molecular Weight | 290.079 | nRing | 3 |
| Solubility: LogS | -2.9 | nHRing | 1 |
| Solubility: LogP | 1.822 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 35 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 21 | No. of Aromatic Carbocycles | 2 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 14 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 12 |
| No. of Oxygen atom | 6 | No. of Arom Bond | 12 |
| nHA | 6 | APOL | 39.1971 |
| nHD | 5 | BPOL | 15.7809 |
| QED | 0.5 |
| Synth | 3.517 |
| Natural Product Likeliness | 1.504 |
| NR-PPAR-gamma | 0.006 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.003 |
| Pgp-sub | 0.003 |
| HIA | 0.015 |
| CACO-2 | -5.405 |
| MDCK | 0.00000563 |
| BBB | 0.054 |
| PPB | 0.825727 |
| VDSS | 3.34 |
| FU | 0.117492 |
| CYP1A2-inh | 0.106 |
| CYP1A2-sub | 0.081 |
| CYP2c19-inh | 0.047 |
| CYP2c19-sub | 0.345 |
| CYP2c9-inh | 0.15 |
| CYP2c9-sub | 0.819 |
| CYP2d6-inh | 0.28 |
| CYP2d6-sub | 0.306 |
| CYP3a4-inh | 0.019 |
| CYP3a4-sub | 0.203 |
| CL | 5.284 |
| T12 | 0.535 |
| hERG | 0.036 |
| Ames | 0.374 |
| ROA | 0.41 |
| SkinSen | 0.555 |
| Carcinogencity | 0.022 |
| EI | 0.16 |
| Respiratory | 0.182 |
| NR-Aromatase | 0.044 |
| Antiviral | Yes |
| Prediction | 0.873646 |